

DT01 Rec'd PTC 2 4 JAN 2005

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of

Application Number Unassigned 4 9 2 1 9 3 0						
Application Number	Unassigned 40 021700					
Filing Date	Herewith					
First Named Inventor	BOYD et al.					
Group Art Unit	Unassigned					
Examiner Name	Unassigned					
Attorney Docket Number	232046					

U.S. PATENT DOCUMENTS						
		U.S. Patent Document			Ţ	
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		*				
			,			

	Foreign Patent Document		nt			Translation	
Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No⁴⁴
AA	wo	00/51589	A2	United States of America, represented by the Secretary, Department of Health and Human Services	Sep. 8, 2000		
ΑВ	wo	02/08231	A2	United States of America, represented by the Secretary, Department of Health and Human Services	Jan. 31, 2002		
							Т
	No.	Doc. No. Office A A WO	Doc. No. Office Application or Patent Number  A A WO 00/51589	Doc. No. Office Application or Patent Number Code  A A WO 00/51589 A2	Doc. No.  Office Application or Patent Number  A A WO 00/51589  A2 United States of America, represented by the Secretary, Department of Health and Human Services  A B WO 02/08231  A2 United States of America, represented by the Secretary, Department of Health and Human Services  AB WO 02/08231  A2 United States of America, represented by the Secretary, Department of Health and Human	Doc. No. Office Application or Patent Number Code	Doc. No. Office Application or Patent Number Code Name of Patentee or Applicant Date of Publication Yes  A A WO 00/51589 A2 United States of America, represented by the Secretary, Department of Health and Human Services  A B WO 02/08231 A2 United States of America, represented by the Secretary, Department of Health and Human Services United States of America, represented by the Secretary, Department of Health and Human

Examiner Doc.		OTHER - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Translation	
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		No*+	
Or	AC	BOWMAN et al., "Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells," PNAS, 85, 7972-7976 (1988)		•	
nı	AD	CANTRELL et al., "Chondropsins A and B: Novel Tumor Cell Growth-Inhibitory Macrolide Lactams from the Marine Sponge Chondropsis sp," <i>J. Am. Chem. Soc.</i> , 122, 8825-8829 (2000)			
NO	ΑE	DRÖSE et al., "BAFILOMYCINS AND CONCANAMYCINS AS INHIBITORS OF V-ATPases AND P-ATPases," J. Exp. Biol., 200, 1-8 (1997)			
ON	AF	DRÖSE et al., "Inhibitory Effect of Modified Bafilomycins and Concanamycins on P- and V-Type Adenosinetriphosphatases," <i>Biochemistry</i> , <i>32</i> , 3902-3906 (1993)			
ON	AG	RASHID et al., "Chondropsin D, a New 37-Membered-Ring Macrolide Lactam from the Marine Sponge Chondropsis Species," <i>J. Nat. Prod.</i> , 64, 1341-1344 (2001)			
NN	АН	RASHID et al., "Application of High-Field NMR and Cryogenic Probe Technologies in the Structural Elucidation of Poecillastrin A, a New Antitumor Macrolide Lactam from the Sponge Poecillastra Species," Organic Lett., 4(19), 3293-3296 (2002)			
OH	ΑI	RASHID et al., "New chondropsin macrolide lactams from marine sponges in the genus Ircinia," <i>Tetrahedron Lett.</i> , 42, 1623-1626 (2001)			

Examiner Signature	Date Considered	19/31	25	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).